Autres langues Cencora, Inc.

Actions

COR

US03073E1055

Equipement, fournitures et distribution médicale

Marché Fermé - NYSE 22:00:03 08/10/2026			Varia. 5j.	Varia. 1 janv.
321,35 ^USD	+1,29%		+7,03%	-4,86%

07/10	Cencora, Inc. : Leerink Partners confirme sa recommandation neutre	ZM
05/10	Un initié de Cencora a vendu des actions pour une valeur de 298 935 dollars, selon un document récent de la SEC	MT

Autres langues

07/10	Cencora : Pharmacy-growth-reimbursement-pressures
05/10	Cencora Insider Sold Shares Worth $298,935, According to a Recent SEC Filing
05/10	Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings Release
02/10	Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings Release
25/09	Cencora, Inc. Announces Appointment of Robert E. Sanchez as Independent Director, Effective October 1, 2026
25/09	Cencora Elects Ryder Systems' Robert Sanchez to Board
25/09	Cencora Elects Robert E. Sanchez to Its Board of Directors
21/09	Cencora : HTAQ Fall 2026 - The price patients pay \| Cencora
08/09	Cencora's MWI Animal Health Merger With Covetrus Sees 'Intensified' FTC Scrutiny, RBC Says
04/09	Cencora : Bringing Oncology Innovation Closer to Patients \| Cencora
02/09	Cencora Launches Cell and Gene Therapy Enablement Service Through Accelerate Pharmacy Solutions
28/08	Walmart settles US government's opioid lawsuit, which sought billions, for $50 million
14/08	Cencora, Inc. Announces Resignation of Lorence H. Kim from the Board, Effective August 13, 2026
12/08	US Equity Markets End Mixed Amid Tech Stock Gains, Lower Inflation Data
12/08	Cencora Says Certain Serviced Walgreens Volume Began Moving Outside Company; Reaffirms 2026 EPS Outlook
05/08	McKesson raises annual profit forecast on strong growth in specialty drug business
05/08	Tranche Update on Cencora, Inc.'s Equity Buyback Plan announced on May 21, 2026.
05/08	Tranche Update on Cencora, Inc.'s Equity Buyback Plan announced on May 1, 2024.
05/08	Cencora, Inc. Declares Quarterly Cash Dividend, Payable on August 31, 2026
05/08	Cencora, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026
05/08	Cencora, Inc. and Innomar Strategies Inc. Enters into an Amended and Restated Credit Agreement
05/08	Cencora : Q3 2026 Cencora Earnings Presentation
05/08	Cencora lifts annual profit view on strong demand for specialty medicines
05/08	Cencora's Fiscal Q3 Adjusted Earnings, Revenue Rise; Raises 2026 Adjusted EPS Guidance
05/08	(COR) Cencora Expects Fiscal 2026 Adjusted EPS Range $17.75 to $17.95, vs. FactSet Est of $17.78